We are living in unprecedented times, as cases of coronavirus (COVID-19) rapidly increase while the world struggles to contain the pandemic. The biotechnology industry has stepped up to help combat this public health threat, working tirelessly to develop potential treatments, diagnostics and…

Biotechnology continues to march forward with new treatments, research and development and technologies that directly impact and improve lives. The best place to learn where the industry is headed and how it is going to get there is at the 2020 BIO International Convention in San Diego, June 8-11…

Are you an innovative biotech company that is R&D-intensive and is developing strategic partnerships within the industry? Enter the Buzz of BIO Contest for your chance to win a complimentary Company Presentation that includes registration at the 2020 BIO International Convention. Buzz of BIO…

Since the beginning of time, production of any kind creates waste. From our gadgets, to our personal care, to our food, growth begets garbage. However, as the planet drowns in our own waste, researchers are finding new and creative ways to reuse our refuse. Some of the best biotech innovations on…

Day #2 of the BIO CEO & Investor Conference was all about the future. How can we ensure the workforce reflects the diverse demographics of the patients the industry serves? What does the future of biotech investment look like? How can we incentivize innovation? Here are some takeaways from …

Last month, the Biotechnology Innovation Organization (BIO) released the first annual report measuring diversity and inclusion in the biotech industry, with real, practical solutions for making the biotech workforce more representative of the industry’s customers and patients. During the BIO CEO …

We’re seeing an “extraordinary level” of biotech innovation, said BIO Chair Jeremy Levin, CEO of Ovid Therapeutics Inc., while kicking off the 22nd BIO CEO & Investor Conference on February 10th in New York. Day #1 of the conference featured discussions about the breakthrough therapies of the…

“The promise for patients has never been better from a scientific point of view,” said BIO CEO and former Member of Congress Jim Greenwood, speaking at the 22nd BIO CEO & Investor Conference in New York. “But it’s the worst of times politically.” Specifically: There are “mountains of political…

As the biotech industry advances scientific discovery around new tumor types and mechanisms of action, we’ve seen more than 2,000 combination trials launched to enhance PD-1/L1 checkpoint inhibitors’ effects on solid tumors. The oncology pipeline has some exciting new biotechnological approaches…

The 22nd annual BIO CEO & Investor Forum kicked off today with a Welcome and Update on BIO's 2020 Initiatives on Behalf of the Industry given by Jeremy Levin, CEO of Ovid Therapeutics Chair of the Board of Directors of BIO. The industry was established in 1970’s during an era of bipartisan…